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ABSTRACT 
We have reviewed the long term results of the first 500 liver transplant 
re:!ipients performed by our group during the cyclosporine era. Three hundred 
and forty-nine recipients lived (69.8%) more than 1 year and the proje:!ted 5 year 
/k!tuarial survival for this sub-grwp of patients is 88%. The two most common 
causes of graft dysfunction after the first year were recwrence of the original 
disease, usually malignancy, and chronic reje:!tion. Most episodes of rejection can 
be controlled with medical treatment; however, 16 patients of 34 patients who 
experienced rejection episodes after the first year reqJired retransplantation. 
Eleven of these 16 are currently alive and free of jaundice. Another common 
cause of late graft dysfunction is biliary strictures. The recqrni:1ed sid! effects 
of cyclosporine such as nephrotoxicity and lymphoproliferative disease have been 
lesser proolems as a result of the judiciws use of the drug. The quality of life 
of long term survivors is excellent. 
INTR)DUC'nON 
It is almost a quarter of a century since the first human liver transplant 
(OLT) was attempted. For the fist 20 of these 25 years, the operation was 
considered experimental and was performed in only a handful of centers 
thrwghwt the world [1-3]. The d!velopment of and use of cycIosporin A (CyA) 
was the turni.ng point in OL T because of the marked improvement in patient 
survival that oocurred as a conseqrence of its use. As a result of its availability, 
the number of transplants and centers performing the operation proliferated world 
wid! [2, 4]. The impact of cyclosporine on short term patients survival after OLT 
has been the topic of many reports; however, information abwt long term survival 
and the gJality of life after OLT during the OjA era is almost nmexistent. 
Herein we report our experience with the first 500 liver transplant recipients 
during the OjA era with the emphasis on those who have survived for more than 
1 year. 
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PATIENTS AND METHODS 
Between March 1980 and Da!ember 1986, 500 patients received liver transplants 
for varying reasons at the University of PittEburgh Hoolth Hospitals. Three 
hundred and three were adults and the remainder were children. «18 years of 
age). The immunOQlppression used in each case consisted of OyA and prednisone 
[2]. The techniques utili2ed for the donor and recipient cperations have been 
reported in detail elsewhere [5]. 
Only patients who 1lll'Vived a full year were considered for this study. The 
following parameters were obtained: the indication for the transplantation, 
duration of 1lll'Vival, causes of death if dead, incidence of rejection, the frequency 
of the causes of. jaundice in the patients and the prevalence of biliary tract 
complications, presence of or history of OyA induced lymphopraliferative disease 
and the quality of. their life. 
Liver function was assessed by determination of the total bilirubin and clinical 
jaundice was defined as a total bilirubin greater than 2mg/dl. renal function was 
considered abnormal if the serum creatinine was greater than 2mg/dl for adults 
and greater than Img/dl for Children. 
Statistild ~ 
Patient survival was calculated by the life table method (BMDP Statistical 
Software, Los Angeles, CA). 
RESULTS 
n; Jpdjmtim 
The original indication for transplantation in the subjects studied is listed in 
Table I. The two most common indication in adults were post necrotic cilThosis 
followed by primary biliary cirrhosis. In children the two most common 
indications were biliary atresia fallowed by any of a Wl'iety of. inborn errors of 
metabolism. In the last group cirrhosis associated with alpha-I-antitrypsin 
deficiency was the most common. 
Other less common metabolic liver disease indications for OLT included 
hemophilia type A although the underlying prcblem in these cases was post 
hepatic cirrhosis, glyc<gen storage disease, cystinosis and cystic fibrosis. 
TABLE I 
DISEASE INDICATION FOR LIVER TRANSPLANTATION DUHNG 
THE CYa.osPOHNE ERA 
Addts OlR<ken 
Aliw Dead Aliw Dead 
Post Hepatic Orrhosis 59 35 18 6 
Biliary Atresia 1 2 66 32 
Primary Biliary Qrrhosis 56 28 
Inborn Errors 18 7 32 11 
Sclerosing Cholangitis 28 12 2 
Primary Tumor 6 18 1 
Familiar Ololestasis 11 3 
Acute Hepatic Failure 3 3 1 3 
Se:!ondary Bil iary 6 4 3 
Orrhosis 
Budd-Chiari 3 4 1 
Cbngenital Fibrosis 1 2 
Neonatal Hepatitis 3 
Trauma 1 1 
Adenoma 2 
Polycystic Disease 2 
Toxic 1 1 
Infection 1 
Idiopathic Purpura 1 
Other 1 
Tom! 187 116 134 63 
303 197 
SURVIVAL 
Three hundred and forty-nine patients (69.8%) &lrvived more than 1 yem. 
Most of the deaths recurring during the first yeBr took plooe within 6 months of 
!UI'gery. The 1 and 5 yem actuarial survival. for the entire group is 69% and 60%, 
respectively. (Figure 1). If one omits from the calculations the patients who 
died within the first yeBr, the projected 6 yeBr actuarial survival. for patients 
surviving the first yeBr is 88% (Figure 2). 
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Figure 1: Actuarial wrvival of the first 500 liver transplant rreipients during the 
cyclosporine era at the University of PittIDurgh. 
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Figure 2: Actuarial 31rvival of the 349 liver transplant rreipients who wrvived 
more than one J1efll'. 
Only 28 (8%) patients who 9Jl'vived the first year died after the first year. 
The causes of their <k!ath are listed in Table II. Eleven of these 28 patients died 
of recurrence of their original disease. The recurrent diseases seen included: 
carcinoma (8 cases), Budd-Oliari (2 cases) and hepatitis (1 case). Nine other 
patients died as a result of chronic rejection or its treatment and the remaining 
patients died of mill!ellaneous causes (Table II). Seventeen additional patients 
died between the first and second year, 8 between the second and third year, 2 
between the third and foorth year and only 1 between the foorth and fifth year 
fallowing OLT. There were no <k!aths after the fifth year of survival fallowing 
OL T with 33 patients at risk. 
TABLE n 
CAUSES OF DEATH OF 28 PA'nENTS WHO SURVIVED AT LEAST 1 YEAR 
POST UVER TRANSPLANT 
Time No. ~ .Ik!um!nee B!jeI!tim Other* Ommeots 
Patients of DisIIa Cbmments 
1-2yrs 17 8* * Rlaurrence 3 6** **Pancrea-
of carcinoma titis and 
(6 cases) sepsis 
hepatitis (2 cases~ 
(1 case) oot ceIl 
Budd-Oliari carcinoma 
(1 case) (1 case) 
and variceol 
hemorrhage 
(1 case) 
2-3yrs 8 3+ +Rlaurrence 5 
of Qmcer 
(2 cases) 
Budd-Oliari 
(1 case) 
3-4yrs 2 0 1 1++ ~ymphopro-
!iferative 
disease and 
aspergill osis. 
4-5yrs 1 0 1 Pancreatitis 
and sepsis 
TofBl 28 11 9 8 
Death due to recurrent disease occurred most often between the first and 
second OLT year, and rejection lead to <k!ath most often between the second and 
th ird years. The numbers in each category are too small for any meaningful 
statistical analysis to be performed. 
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Two patients died as a resul t of seizures caused by acute arterial 
hypertension prOOably seconcmy to OjA toxicity. These two patients suffered 
severe hypoxia which resulted in cerebral injury and all<graft fttilure. Two other 
patients died of pancreatitis, sepsis and graft fttilure. Another patient died of 
gastrointestinal bleeding and all<graft fttilure due to rethrombosis of the portal 
vein and the last patient died of an 08t cell carcinoma of the lung. Finally, two 
more patients died after 3 years post-transplantation of diseminated 
lymphoproliferative disease and complications of pancreatitis, respec:ltively. 
a.INICAL JAUNDICE 
Itjeqtim 
Two hundred and ninety-five out of 349 (85%) patients who survived more 
than 1 yeJr are free of jaundice (up to June 30, 1987~ however, 54 (15%) patients 
have experienced at least one episode of clinical jaundice (bilirubin >2mg/dl 
postoperatively. The most common cause of postoperative jaundice was reja:tion 
(Table III). A total of 34 out of 54 (63%) patients had at least 1 episode of 
reja:tion severe enwgh to require re-hospitalimtion. In 16 of these 34 cases the 
reja:tion episode was brwght under control with medical treatment with the 
exception of 1 patient, who died of unrelated causes in this group of 16 cases. 
The other 15 currently haw a total bilirubin of less than 2mg/dl at the time of 
the last follow-up. 
TABLE III 
CAUSES OF JAUNDICE AFTER ORmOTOPIC LIVER TRANSPLANTA110N 
IN PAl1ENTS WHO SURVIVE MOIm THAN ONE YEAR 
H=ja:tion requiring 16 11 5 
retransplantation 
H=ja:tion treated 18 16 2 
medically 
Bil iary tract 16 9 7 
strictures 
M i!l!ellaneous 4 1 3 
TOTAL 54 3'1 1'1 
!bwssllil = bilirWin < 2mg/d at last fdlow-up 
Una ........... i1 = bBirmin > 7mg/d at last follow-up 
One of the remaining 18 patients died of rejection while waiting for 
retransplantation and another is currently awaiting retranl'plantation. 
The remaining 16 patients with at least one episoOO of rejection underwent 
liver retransplantation because of failure of medical treatment to control their 
rejection. Eleven of these patients (69%) are alive with no evidence of clinical 
jaundice ( <2mg/dl) at the time of the last follow-up. The other 5 died of 
complications of the retransplantation experience. 
Six patients not induced among the 34 patients di~ussed above had rejection 
in addition to one or more intrahepatic biliary strictures. Five of these 6 
patients were retransplanted and 2 of them are doing well and are free of 
jaundice. Three of the 6 died of retransplantation complications and the sixth 
patient is currently on the waiting list for a second tranl'plant. 
BlLIARY OOMPUCA nONS 
Sixteen of 54 (30%) patients with postoperative jaundice experienced 
jaundice because of one or more biliary strictures. These strictures <Xn1I' both at 
the level of the bile duct anastomosis and within the liver. Eight of these 
patients (50%) had a wooessful surgical correction of the biliary stricture. In 
general, the surgical intervention consisted of converting a previous end-to-end 
choledocholedochostomy to an end-to-side choiedochojejunCBtomy using a Ibux-en-
Y limb. Another patient, a 4 year old female with multiple intrahepatic strictures 
due to thrombosis of the hepatic artery received a secondary transplant. 
Five of these 16 patients have persistent jaundice as a result of their biliary 
stricture. Two of these 5 have had surgical reconstructions, but the procedures 
were unsuccessful since these patients may have ongoing chronic rejection. 
Another patient is a 3 year old who received a liver tranl'plant for biliary 
atresia. This child has complete obstruction of the junction of the main bile 
ducts and his biliary system is drained externally throogh a percutaneous catheter. 
Althoogh this child is free of jaundice, he is a candidate for retranl'plantation 
because of the problems associated with the chronic indwelling catheter. Another 
patient with intrahepatic biliary strictures in the all~raft may have recurrence of 
his original ~erosing cholangitis althoogh it is difficult if not impossible to 
prove this conclusion. Althoogh this patient had his OLT 2 years ago, he is 
currently free of jaundice but his serum transaminases are twice normal and the 
alkaline phosphatase is 910 IU/ml [6]. The fifth patients is a 32 year old man 
who was transplanted because of a fibrolamellar tumors involving the liver. 
Uirrently he has intrahepatic strictures and recurrence of the neoplasm. His 
hepatic chemistries are close to normal. 
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MISCELLANEOUS CAUSES 
After the first year clinical jaundice CX!CUl'l'ed in 2 patients breause of 
recurrence of viral hepatitiS; one of these 2 has died and the other is doing well 
after retransplantation. Two other patients have had a recurrence of their 
original. tumor and both have died. A fifth patient died with allograft lRilure die 
to pancreatitis and septicemia. Another patient died of recurrent alcoholism and 
allograft rejection. Lastly, a sixth patient who received a liver transplant 
because of a fudd-01iari syndrome died of recurrence of her disease when the 
anticoogulation she was on was dil:Continued for a liver biopsy. 
RENAL FAILURE 
Twenty adult patients have a serum creatinine greater than 2mg/dl at the 
time of the last follow-up. In 3 of these patients, the OyA has been dil:Continued 
breause of d:!terioration of their renal function. In each case these patients are 
being maintained on an immunosuppressive regimen consisting of a combination of 
Il21l.thioprine and prednisone. 
Thirteen surviving children ( <18 years of age) have a serum creatinine 
greater than lmg/dl at the time of the last follow-up. None of the adult or 
children who have survived for more than 1 year have required dialysis for renal. 
dysfunction. 
LYMPHOPIDLIFERAl1VE DISEASE 
Fifteen of the 500 patients transplanted during this period have d:!vel.oped a 
post-transplant lymphoproliferative disease (3.0%). The onset of the disease in 9 
of these 15 patients tad< plOC!e during the first year after transplantation. In the 
remaining 6 the disease d:!vel.oped after the first yes.r but between the first and 
second year in 3, between the second and third year in 1, and after the third 
yes.r in 2 others. Lymphoproliferative disease has been treated sureessfully in 3 
of these 6 patients by either decreasing or temporarily discontinuing 
immunosuppression. One patient currently has a lymphopraliferative disease 
involving the retroperitoneum and mesenteric nodes cEspite dil:Continuation of his 
immunosuppression for 11 months and 2 d:!bulking laparotomies. Another child has 
had repetitive recurrences of lymphoproliferative tumors in the trachea. 
Reductions in CyA usage in this case has not resulted in resolving the 
lymphoproliferative problem. The sixth patient died of disseminated 
lymphoproliferative disease involving the retroperitoneum, kidneys, adrenals, heart, 
brain, bone marrow and gastrointestinal tract. A summary of these 6 patients is 
given in Table IV and a recent review of this subject has been published [7]. 
TABLE IV 
LYMPHOPIDLIFERATIVE DISEASE IN IlVER TRANSPLANT 
REaPIFNTS WHO HAVE SURVIVED MOIm THAN 1 YEAR 
<lise Age 
at TX 
1 8 
2 15 
3 4 
4 5 
5 3 
6 7 
time of onset Organs 
of PTLD after Invdwed 
OLT (mootbs) 
39 lymph nO<Es 
kidneys, adrenals 
heart, bone 
marrows, CNS, 
GI tract 
16 lymph nodes 
CNS, nasopharynx 
24 retroperitoneal 
and mesenteric 
lymph nC>d:!s, 
GI tract 
48 trachea 
12 nasopharynx 
cervical nodes 
13 nasopharynx 
cervical nodes 
QUAIlTY OF LIFE 
TreIltment 
none 
transient 
direontinuation 
of immuno-
suppression 
direontinuation of 
immunosuppression 
reduction of 
immunosuppression 
reduction of 
immunosuppression 
reduction of 
immunosuppression 
died 
no resiciJal 
tumor 
residual 
tumor 
recent 
recurrence 
no resi<ilal 
tumor 
no residual 
tumor 
The qJality of life following OLT was assessed in 37 patients who have 
survived more than 5 years after hepatic transplantation. Twenty-one of these 37 
are children ( <18 years old) and 16 are adults. One of these long term surviving 
children has a neural~ic deficit as a result of recurrence of the original lipid 
stcnlge disease. This case has been reported elsewhere [8]. A second child has 
<kreased visual acuity due to a pseudotumor, but his liver function is normal. A 
third child has abnormal transaminase levels although he is not jaundiced. A liver 
biopsy in this case showed a reduction in the number of the bile ducts within the 
Ii ver. Finally, a fourth child who experienced portal vein thrombosis 
postoperatively has required rlerotherapy for variceal hemorrhage; however, this 
child has been doing very well with no subSle<Jlent episodes of bleeding (for the 
last year). The remainder of the children are growing well, attend rehoal and are 
free of jaundice. 
Among the 16 adults who are long term survivors, one patient has recurrence 
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of a hepatreeJ.lular carcinoma involving the lungs. Another has daveloped chronic 
renal failure due to CyA and at the present time is being treated with 
azathioprine instead of OjA. Dialysis is not necessary. A third patient is 
disabled because of a severe neurologic deficit sustained during the liver 
transplantation procedure. A fourth patient is on triple drug therapy 
(82Bthioprine, cyclosporine and prednisone) after experiencing a recent episode of 
rejeation. Nonetheless, she is working full time. Fwr patients are housewives 
and require no outside help and the remaining 8 are currently working full time. 
Among the 37 patients who have survived 5 years or more, only 5 patient 
required a seaond transplant and none have required a third transplant. 
DISCUSSI:ON 
Liver transplantation is the treatment of choice for patients with hopelessly 
advanced chronic liver disease. The operation has become a routine prooedure in 
many centers throughout the world. Despite the overall good results with OLT, it 
should be remembered that serious complications can oocur following hepatic 
transplantation. Several factors have been implicated in their pathcgenic and 
include the difficulty with the operation and the previous condition of the 
recipient. 
Most of the complications and daaths following liver transplantation oocur 
during the flrst year and almost 90% of the patients who survived the flrst year 
can be expeated to be alive at 5 years. The most common causes of death after 
the first year are recurrence of the original disease and rejeation [9]. Most 
patients who died of recurrent disease did so between the flrst and seaond year 
after transplantation. R;currence of hepatic malignancy accounts for the majority 
of these cases [10]. Iejeation, on the other hand, oocurs more often between the 
second and third post OLT year. An explanation for this late onset of rejeation 
which leads to patient daath may be that most patients at this time are taking 
very small doses of immunosuppression which may not be optimal f<r allc:graft 
immunotolerance. 
Biliary strictures are a ftoeq.ient cause of jaundice in patients who survive 
more than 1 year [11]. In several of these patients, the clinical presentation has 
been similar to that associated with rejeation and the biliary strictures were 
ruspeated only after no improvement oocurred after a full couroo of anti-rejeation 
therapy. Ultrasound has not been useful. in these cases and if a biliary stricture 
is wspeated a percutaneous cholangicgraphy is absolutely indicated. 
The introduction of OjA into the clinical practice of transplantation was 
followed by significant concerns about its side effects, namely nephrotoxicity and 
malignancy. However, the nephrotoxiCity associated with long term use of OjA 
has been minimi2Ed by adjusting the doses according to renal function and the 
addition of 82athiq>rine when necessary. In Jlict, O:!A has had to be dilContinued 
in only 3 patients because of nephrotoxicity. Fortunately, effective 
immunosuppression in these 3 patients has been II!hieved with a combination of 
82athiq>rine and prednisone. A second major concern with the chronic use of 
O:!A is immunosuppression-induced lymphq>roI.iferative disease. Most patients with 
this prd>lem respond to drastic reductions or dilContinuation of their O:!A. It 
appears as if the sooner such a complication is detected, the better is the 
pr<gnosis. Thus, lesions that are detected eorly seem to respond quickly to a 
rediction in the immunosuppression being used. 
The <JIBlity of life of most long term liver transplant survivors is excellent. 
Fallowing OL T children have been shown to have normal growth patterns [12]. 
The reintegration of both children and adult survivors bll!k into society is very 
high, the majority either attend IChoal or work full time. 
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